Unicycive Therapeutics

Q2 FY2026 EarningsQ2 FY26 reported a significant beat on Diluted EPS, posting -$0.06 vs. consensus mean of -$0.3286, largely driven by a non-cash $8.0M gain from the change in fair value of warrant liabilities. However, operating expenses increased 46% YoY to $10.1M, exceeding implied expectations due to a surge in stock-based compensation ($2.9M). A second CRL from the FDA for Oxylanthanum Carbonate (OLC) on June 30, 2026, due to third-party manufacturing deficiencies, remains the primary headwind despite no clinical safety or efficacy concerns.